[go: up one dir, main page]

WO2008013807A3 - A novel lactic acid formulation of mk-0457 useful for the treatment of cancer - Google Patents

A novel lactic acid formulation of mk-0457 useful for the treatment of cancer Download PDF

Info

Publication number
WO2008013807A3
WO2008013807A3 PCT/US2007/016637 US2007016637W WO2008013807A3 WO 2008013807 A3 WO2008013807 A3 WO 2008013807A3 US 2007016637 W US2007016637 W US 2007016637W WO 2008013807 A3 WO2008013807 A3 WO 2008013807A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
useful
treatment
lactic acid
acid formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/016637
Other languages
French (fr)
Other versions
WO2008013807A2 (en
WO2008013807A9 (en
Inventor
David C Dubost
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Priority to JP2009521803A priority Critical patent/JP2009544705A/en
Priority to AU2007277226A priority patent/AU2007277226A1/en
Priority to EP07796994A priority patent/EP2051737A2/en
Priority to CA002658436A priority patent/CA2658436A1/en
Publication of WO2008013807A2 publication Critical patent/WO2008013807A2/en
Publication of WO2008013807A3 publication Critical patent/WO2008013807A3/en
Anticipated expiration legal-status Critical
Publication of WO2008013807A9 publication Critical patent/WO2008013807A9/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A lactic acid formulation, and a process to prepare that formulation, of MK-0457 is disclosed:. Such a formulation is useful in the treatment of cancer.
PCT/US2007/016637 2006-07-26 2007-07-24 A novel lactic acid formulation of mk-0457 useful for the treatment of cancer Ceased WO2008013807A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2009521803A JP2009544705A (en) 2006-07-26 2007-07-24 MK-0457 novel lactic acid formulation useful for cancer treatment
AU2007277226A AU2007277226A1 (en) 2006-07-26 2007-07-24 A novel lactic acid formulation of MK-0457 useful for the treatment of cancer
EP07796994A EP2051737A2 (en) 2006-07-26 2007-07-24 A novel lactic acid formulation of mk-0457 useful for the treatment of cancer
CA002658436A CA2658436A1 (en) 2006-07-26 2007-07-24 A novel lactic acid formulation of mk-0457 useful for the treatment of cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83344206P 2006-07-26 2006-07-26
US60/833,442 2006-07-26

Publications (3)

Publication Number Publication Date
WO2008013807A2 WO2008013807A2 (en) 2008-01-31
WO2008013807A3 true WO2008013807A3 (en) 2008-04-03
WO2008013807A9 WO2008013807A9 (en) 2009-03-12

Family

ID=38863098

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/016637 Ceased WO2008013807A2 (en) 2006-07-26 2007-07-24 A novel lactic acid formulation of mk-0457 useful for the treatment of cancer

Country Status (6)

Country Link
EP (1) EP2051737A2 (en)
JP (1) JP2009544705A (en)
CN (1) CN101500613A (en)
AU (1) AU2007277226A1 (en)
CA (1) CA2658436A1 (en)
WO (1) WO2008013807A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10752612B2 (en) 2015-04-17 2020-08-25 Ludwig Institute For Cancer Research Ltd PLK4 inhibitors

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6591036B2 (en) 2016-02-26 2019-10-16 公益財団法人がん研究会 Screening method and evaluation system of anticancer agent focusing on HP1 function

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007014250A2 (en) * 2005-07-26 2007-02-01 Vertex Pharmaceuticals Incorporated Abl kinase inhibition
WO2007136615A2 (en) * 2006-05-16 2007-11-29 Merck & Co., Inc. Combination cancer therapy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007014250A2 (en) * 2005-07-26 2007-02-01 Vertex Pharmaceuticals Incorporated Abl kinase inhibition
WO2007136615A2 (en) * 2006-05-16 2007-11-29 Merck & Co., Inc. Combination cancer therapy

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DOGGRELL SHEILA A: "Dawn of Aurora kinase inhibitors as anticancer drugs.", EXPERT OPINION ON INVESTIGATIONAL DRUGS SEP 2004, vol. 13, no. 9, September 2004 (2004-09-01), pages 1199 - 1201, XP002467064, ISSN: 1744-7658 *
HARRINGTON E A ET AL: "VX-680, A Potent and Selective Small-Molecule Inhibitor of the Aurora Kinases, Suppress Tumor Growth In Vivo", NATURE MEDICINE, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 10, no. 3, March 2004 (2004-03-01), pages 262 - 267, XP003014821, ISSN: 1078-8956 *
WANG Y ET AL: "VX-680/MK-0457. Aurora kinase inhibitor oncolytic", DRUGS OF THE FUTURE 2007 SPAIN, vol. 32, no. 2, 2007, pages 144 - 147, XP002467063, ISSN: 0377-8282 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10752612B2 (en) 2015-04-17 2020-08-25 Ludwig Institute For Cancer Research Ltd PLK4 inhibitors

Also Published As

Publication number Publication date
WO2008013807A2 (en) 2008-01-31
CA2658436A1 (en) 2008-01-31
CN101500613A (en) 2009-08-05
JP2009544705A (en) 2009-12-17
EP2051737A2 (en) 2009-04-29
WO2008013807A9 (en) 2009-03-12
AU2007277226A1 (en) 2008-01-31

Similar Documents

Publication Publication Date Title
WO2009151910A3 (en) Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer
EP2273975B8 (en) Pharmaceutical solutions, process of preparation and therapeutic uses
EP4327867A3 (en) Pharmaceutical composition comprising glucopyranosyl diphenylmethane derivatives, pharmaceutical dosage form thereof, process for their preparation and uses thereof for improved glycemic control in a patient
TN2012000428A1 (en) Bisaryl-bonded aryltriazolones and use thereof
JO2756B1 (en) 4T 4-(4- Cyano-2-thioaryl)dihydropyrimidinones and use thereof
WO2008104306A3 (en) Substituted 4-aryl-1,4-dihydro-1,6-naphthyridinamides and use thereof
WO2009105774A3 (en) Amino acid inhibitors of cytochrome p450
WO2007106537A3 (en) Aminoquinolones as gsk-3 inhibitors
WO2008086462A3 (en) AMINO-SUBSTITUTED QUINAZOLINE DERIVATIVES AS INHIBITORS OF β-CANTENIN/TCF-4 PATHWAY AND CANCER TREATMENT AGENTS
WO2008119457A3 (en) Lactam-substituted dicarboxylic acids and use thereof
WO2008136394A1 (en) Method for production of lactam compound, and intermediate for the production method
WO2007105015A3 (en) DERIVATIVES OF 18ß-GLYCYRRHETINIC ACID
UA102238C2 (en) 4-(4-cyano-2-thioaryl)dihydro-pyrimidinones and use thereof
WO2010088450A3 (en) Arylamide derivatives useful in the treatment of diseases associated with serca activity
WO2008022345A3 (en) Compositions and methods for inhibiting cytochrome p450
WO2008052139A3 (en) Ultra low dose doxepin and methods of using the same to treat sleep disorders
WO2009035634A3 (en) Cyanoaminoquinolones and tetrazoloaminoquinolones as gsk-3 inhibitors
WO2009099553A3 (en) Use of kinase inhibitor in treatment of atherosclerosis
WO2010090494A3 (en) Medical use of 5-benzylaminosalicylic acid derivatives or salts thereof
WO2010121675A3 (en) Thiazolyl-benzimidazoles
UA92861C2 (en) Pharmaceutical composition for treating depression and process for the preparation thereof
WO2010072770A3 (en) Griseofulvin analogues for the treatment of cancer by inhibition of centrosomal clustering
WO2008019782A3 (en) Dispersions of nanoureas containing active ingredients
TW200724532A (en) Pyrimidinecarboxylic acid derivatives and their use
WO2007018588A8 (en) Stable pharmaceutical composition comprising linezolid form iv

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780028724.5

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07796994

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2658436

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 428/DELNP/2009

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2009521803

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2007277226

Country of ref document: AU

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2007277226

Country of ref document: AU

Date of ref document: 20070724

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2007796994

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: RU